Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ultragenyx Pharma (RARE) Reports Q4 Loss of $0.37 on Revenues of $91.54M
February 11, 2021 4:45 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($0.37), versus ($1.62) reported last year. Revenue for the quarter came in at $91.54 million, versus $35.59 million reported last year.
Last year was a transformative year as we received two approvals, generated clinically meaningful data in our gene therapy and... More
